Alterations in the hippocampal endocannabinoid system in diet-induced obese mice.
The endocannabinoid (eCB) system plays central roles in the regulation of food intake and energy expenditure. Its alteration in activity contributes to the development and maintenance of obesity. Stimulation of the cannabinoid receptor type 1 (CB(1) receptor) increases feeding, enhances reward aspects of eating, and promotes lipogenesis, whereas its blockade decreases appetite, sustains weight loss, increases insulin sensitivity, and alleviates dysregulation of lipid metabolism. The hypothesis has been put forward that the eCB system is overactive in obesity. Hippocampal circuits are not directly involved in the neuronal control of food intake and appetite, but they play important roles in hedonic aspects of eating. We investigated the possibility whether or not diet-induced obesity (DIO) alters the functioning of the hippocampal eCB system. We found that levels of the two eCBs, 2-arachidonoyl glycerol (2-AG) and anandamide, were increased in the hippocampus from DIO mice, with a concomitant increase of the 2-AG synthesizing enzyme diacylglycerol lipase-alpha and increased CB(1) receptor immunoreactivity in CA1 and CA3 regions, whereas CB(1) receptor agonist-induced [(35)S]GTPgammaS binding was unchanged. eCB-mediated synaptic plasticity was changed in the CA1 region, as depolarization-induced suppression of inhibition and long-term depression of inhibitory synapses were enhanced. Functionality of CB(1) receptors in GABAergic neurons was furthermore revealed, as mice specifically lacking CB(1) receptors on this neuronal population were partly resistant to DIO. Our results show that DIO-induced changes in the eCB system affect not only tissues directly involved in the metabolic regulation but also brain regions mediating hedonic aspects of eating and influencing cognitive processes.
Massa
Federico
F
Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg University, D-55099 Mainz, Germany.
Mancini
Giacomo
G
Schmidt
Helmut
H
Steindel
Frauke
F
Mackie
Ken
K
Angioni
Carlo
C
Oliet
Stéphane H R
SH
Geisslinger
Gerd
G
Lutz
Beat
B
D000818:Animals; D001095:Arachidonic Acids / Q000378:metabolism; D063385:Cannabinoid Receptor Modulators / Q000096:biosynthesis / Q000378:metabolism*; D004041:Dietary Fats / Q000008:administration & dosage; D004195:Disease Models, Animal; D063388:Endocannabinoids; D005989:Glycerides / Q000378:metabolism; D006624:Hippocampus / Q000378:metabolism* / Q000502:physiology; D008071:Lipoprotein Lipase / Q000378:metabolism; D036881:Long-Term Synaptic Depression / Q000502:physiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009474:Neurons / Q000378:metabolism / Q000502:physiology; D009765:Obesity / Q000139:chemically induced / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D053284:Polyunsaturated Alkamides / Q000378:metabolism; D043884:Receptor, Cannabinoid, CB1 / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D013569:Synapses / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000235:genetics
D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D004041:Dietary Fats; D063388:Endocannabinoids; D005989:Glycerides; D053284:Polyunsaturated Alkamides; D043884:Receptor, Cannabinoid, CB1; D005680:gamma-Aminobutyric Acid; C094503:glyceryl 2-arachidonate; D008071:Lipoprotein Lipase; C078814:anandamide
Brain Res. 2003 Sep 12;984(1-2):33-41
12932837
Int J Obes (Lond). 2006 Apr;30 Suppl 1:S19-23
16570100
Neurosci Biobehav Rev. 2004 May;28(3):261-71
15225970
Science. 2007 May 25;316(5828):1212-6
17525344
Neuron. 2003 Aug 14;39(4):599-611
12925275
J Physiol. 2005 Dec 1;569(Pt 2):501-17
16179366
J Neurosci. 2002 May 15;22(10):3864-72
12019305
Physiol Rev. 2009 Jan;89(1):309-80
19126760
Int J Obes Relat Metab Disord. 2004 Apr;28(4):640-8
14770190
J Neurosci. 2007 Jan 3;27(1):46-58
17202471
Nat Rev Drug Discov. 2008 May;7(5):438-55
18446159
Physiol Behav. 1986;38(3):321-6
3786511
Nat Neurosci. 2010 Mar;13(3):281-3
20139974
Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):123-42
12052031
J Physiol. 2006 Nov 15;577(Pt 1):263-80
16973696
Obesity (Silver Spring). 2007 Apr;15(4):798-808
17426312
Cell Metab. 2010 Apr 7;11(4):273-85
20374960
Neuron. 2010 Feb 11;65(3):320-7
20159446
J Nutr Health Aging. 2000;4(4):202-7
11115801
J Neurosci. 2010 Feb 10;30(6):2017-24
20147530
J Neurosci. 2005 Jul 20;25(29):6845-56
16033894
Mol Pharmacol. 2009 Dec;76(6):1220-7
19767452
J Pharmacol Exp Ther. 2000 Oct;295(1):328-36
10991998
Neuroimage. 2004 Dec;23(4):1486-93
15589112
Curr Opin Pharmacol. 2009 Feb;9(1):46-52
19157983
Endocr Rev. 2006 Feb;27(1):73-100
16306385
J Pharmacol Exp Ther. 2009 Nov;331(2):591-7
19666749
Neuron. 2006 Aug 17;51(4):455-66
16908411
J Clin Invest. 2003 Aug;112(3):423-31
12897210
Brain Res Rev. 2006 Jun;51(1):85-107
16364446
Neuropharmacology. 2008 Dec;55(7):1140-6
18675282
Neuron. 2003 May 8;38(3):461-72
12741992
J Neuroendocrinol. 2008 Nov;20(11):1288-94
18752650
Brain Res. 2002 Oct 18;952(2):232-8
12376184
J Neuroendocrinol. 2008 May;20 Suppl 1:139-46
18426513
Nature. 2001 Apr 12;410(6830):822-5
11298451
Nature. 2002 Aug 1;418(6897):530-4
12152079
J Physiol. 2007 Jan 1;578(Pt 1):233-47
17053036
Eur J Neurosci. 1999 Dec;11(12):4213-25
10594647
Neuroimage. 2005 Jan 15;24(2):436-43
15627585
Neuron. 2001 Aug 16;31(3):453-62
11516401
Neuroscience. 2002;112(4):803-14
12088740
Handb Exp Pharmacol. 2008;(184):435-77
18064422
Nat Neurosci. 2006 Mar;9(3):381-8
16491079
Lancet. 2005 Apr 16-22;365(9468):1389-97
15836887